[1]夏雨婷,唐文熙.生命周期卫生技术评估的国际实践与启示[J].卫生经济研究,2026,43(06):25-29.
　XIA Yuting,TANG Wenxi.International Practices and Implications of Lifecycle Health Technology Assessment[J].Journal Press of Health Economics Research,2026,43(06):25-29.
点击复制

生命周期卫生技术评估的国际实践与启示

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
43
期数:
2026年06期
页码:
25-29
栏目:
卫生技术评估
出版日期:
2026-06-03

文章信息/Info

Title:
International Practices and Implications of Lifecycle Health Technology Assessment
作者:
夏雨婷1; 唐文熙1
1.中国药科大学国际医药商学院，江苏 南京 211198
Author(s):
XIA Yuting;  TANG Wenxi
School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing Jiangsu 211198, China
关键词:
生命周期卫生技术评估; 卫生技术评估; 真实世界证据; 价值医疗
Keywords:
lifecycle health technology assessment;  health technology assessment;  real-world evidence;  value-based healthcare
分类号:
R19
文献标志码:
A
摘要:
生命周期卫生技术评估突破传统卫生技术评估的单次静态评估模式，通过动态、迭代的证据生成与决策优化机制，构建覆盖技术研发、准入、使用至退出的全周期管理框架，是全球卫生技术管理领域的前沿方向。加拿大、英国、法国的实践为生命周期卫生技术评估的应用提供了宝贵经验。基于我国卫生技术评估的发展现状，可通过选择优先领域试点、强化真实世界证据应用、构建多方协作体系以及加强卫生技术评估标准化建设等，积极探索生命周期卫生技术评估的本土化路径，助力实现价值医疗。
Abstract:
Lifecycle Health Technology Assessment(LC-HTA) breaks away from the traditional model of one-time, static health technology assessment, and establishes a comprehensive lifecycle management framework covering technology development, market access, utilization, and exit, by the dynamic, iterative mechanisms for evidence generation and decision optimization, which represents a cutting-edge direction in the global field of health technology management. The practices in Canada, the United Kingdom, and France offer valuable insights for the application of LC-HTA. Based on the current development status of health technology assessment in China, it is necessary to actively explore the localization path of LC-HTA by selecting priority areas for pilot programs, strengthening the application of real-world evidence, establishing a multi-stakeholder collaboration system, and enhancing the standardization of health technology assessment. These efforts will facilitate the realization of value-based healthcare.

参考文献/References:

[1] O'Rourke B, Oortwijn W, Schuller T. The new definition of health technology assessment: a milestone in international collaboration[J]. International Journal of Technology Assessment in Health Care, 2020, 36(03): 187-190.
[2] Pichler F B, Boysen M, Mittmann N, et al. Lifecycle HTA: promising applications and a framework for implementation. An HTAi Global Policy Forum Task Force report[J]. International Journal of Technology Assessment in Health Care, 2024, 40(01): e50.
[3] Trowman R, Powers A, Ollendorf D A. Considering and communicating uncertainty in health technology assessment[J]. International Journal of Technology Assessment in Health Care, 2021, 37(01): e74.
[4] Trowman R, Migliore A, Ollendorf D A. Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment[J]. International Journal of Technology Assessment in Health Care, 2023, 39(01): e15.
[5] Regier D A, Pollard S, Mcphail M, et al. A perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada[J]. NPJ Precision Oncology, 2022, 6(01): 76.
[6] Kirwin E, Round J, Bond K, et al. A conceptual framework for Life-Cycle Health technology assessment[J]. Value in Health, 2022, 25(07): 1116-1123.
[7] PCODR. PCODR Expert Review Committee(pERC): Final Recommendation Larotrectinib[EB/OL]. [2025-05-07]. https://www.cda-amc.ca/sites/default/files/pcodr/Reviews2019/10159LarotrectinibNTRK2BSolidTumours_fnRec_REDACT_31Oct201_ChairAppro-ved_final.pdf.
[8] Excellence N I. Early Value Assessment(EVA) for medtech[EB/OL]. [2025-05-05]. https://www.nice.org.uk/about/what-we-do/eva-for-medtech.
[9] de Santé H A. Early access authorisation: a positive initial report and refined assessment methods[EB/OL]. [2025-05-05]. https://www.has-sante.fr/jcms/p_3340090/en/early-access-authorisation-a-positive-initial-report-and-refined-assessment-methods.
[10] de Santé H A. Authorisation for early access to medicinal products: HAS assessment doctrine[EB/OL]. [2025-05-05]. https://www.has-sante.fr/upload/docs/application/pdf/2021-08/authorisation_ for_early_access_to_medicinal_products_has_assessment_doctr-ine.pdf.
[11] de Santé H A. Autorisation d'accès précoce aux médicaments: doctrine d'évaluation de la HAS[EB/OL]. [2025-08-10]. https://www.has-sante.fr/upload/docs/application/pdf/2021-06/acces_precoces_-_doctrine.pdf.
[12] Martin T, Rioufol C, Favier B, et al. Impact of early access reform on oncology innovation in France: approvals, patients, and costs[J]. Bio Drugs, 2024, 38(03): 465-475.
[13] Crespel V, Roux G, Desbiolles A, et al. OP35 early access to medicinal products in France: a positive evaluation two years into the new framework[Z]. 2024: 40, S16.
[14] Pichler F B, Boysen M, Mittmann N, et al. An operationalization framework for lifecycle health technology assessment: a Health Technology Assessment International Global Policy Forum Task Force report[J]. International Journal of Technology Assessment in Health Care, 2024, 40(01): e45.
[15] 国家医疗保障局办公室关于开展真实世界医保综合价值评价试点工作的通知[EB/OL].[2025-09-23].https://www.nhsa.gov.cn/art/2025/9/23/art_109_17984.html.

相似文献/References:

[1]黄 理,路 云,段承阿鑫.卫生技术评估在高值医用耗材供应保障中的应用价值及其实现[J].卫生经济研究,2018,(10):10.
　HUANG Li,LU Yun,DUAN Cheng-a-xin.The Application Value and Its Realization of Health Technology Assessment in the Supply Security of High-value Medical Consumables[J].Journal Press of Health Economics Research,2018,(06):10.
[2]金春林,王海银,孙 辉,等.价值医疗的概念、实践及其实现路径[J].卫生经济研究,2019,(02):6.
　JIN Chun-lin,WANG Hai-yin,SUN Hui,et al.The Concept, Progress and Practice Path of Value-based healthcare[J].Journal Press of Health Economics Research,2019,(06):6.
[3]傅 卫,赵 琨.中国卫生技术评估的发展与挑战[J].卫生经济研究,2019,(03):3.
　FU Wei,ZHAO Kun.Development and Challenges of China's Health Technology Assessment[J].Journal Press of Health Economics Research,2019,(06):3.
[4]张 宸,金秋晨,陈永法.儿童药卫生技术评估的特殊性——以英国NICE儿童药评估为例[J].卫生经济研究,2021,38(11):51.
　ZHANG Chen,JIN Qiu-chen,CHEN Yong-fa.Particularity of Health Technology Assessment for Children's Drug——Taking NICE Children's Drug Assessment as an Example[J].Journal Press of Health Economics Research,2021,38(06):51.
[5]金秋晨,张 宸,陈永法.抗肿瘤药物联合疗法价值归因探索[J].卫生经济研究,2023,40(10):74.
　JIN Qiuchen,ZHANG Chen,CHEN Yongfa.Study on the Value Attribution of Antitumor Drug Combination Therapy[J].Journal Press of Health Economics Research,2023,40(06):74.
[6]郑王彪,郑 超,孙 强.医保药品目录动态调整的国际经验与启示[J].卫生经济研究,2023,40(12):62.
　ZHENG Wangbiao,ZHENG Chao,SUN Qiang.International Experience and Enlightenment on the Dynamic Adjustment of Medical Insurance Drug Catalog[J].Journal Press of Health Economics Research,2023,40(06):62.
[7]杨婷婷,薛允莲,吴伟旋,等.高值医用耗材评价的难点分析与方法优化 ——基于多维度分析[J].卫生经济研究,2025,42(11):54.
　YANG Tingting,XUE Yunlian,WU Weixuan,et al.Analysis of Challenges and Optimization of Methods in the Evaluation of High-Value Medical Consumables ——Based on a Multi-Dimensional Analysis[J].Journal Press of Health Economics Research,2025,42(06):54.
[8]骆依静,许 军,陈星伟,等.药品价值评价的全球趋势与中国实践研究[J].卫生经济研究,2026,43(02):47.
　LUO Yijing,XU Jun,CHEN Xingwei,et al.Research on Global Trends and Chinese Practice in Drug Value Assessment[J].Journal Press of Health Economics Research,2026,43(06):47.
[9]崔雅婷,王俊斐,徐彩花,等.全球卫生技术评估研究热点与发展趋势[J].卫生经济研究,2026,43(03):6.
　CUI Yating,WANG Junfei,XU Caihua,et al.Analysis of Research Hotspots and Development Trends in Health Technology Assessment[J].Journal Press of Health Economics Research,2026,43(06):6.
[10]徐志浩,王 健,谭佳龙.医保决策中真实世界数据的应用实践与启示 ——以NICE药品准入评估中的决策调整因子为例[J].卫生经济研究,2026,43(06):34.
　XU Zhihao,WANG Jian,TAN Jialong.Practical Applications and Insights of Real-World Data in Health Insurance Decision-Making ——Taking Decision Modifiers of Drug Access Assessment in NICE as an Example[J].Journal Press of Health Economics Research,2026,43(06):34.

更新日期/Last Update: 2026-06-03